What is RYTM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 6.25B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RYTM?

P/E (TTM) is n/a and 52-week range is $74.50 to $122.20 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RYTM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RYTM?

The company profile lists revenue (TTM) near $240M, net income (TTM) near $-20.52B, EPS (TTM) near $-3.05 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rhythm Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 68.5M shares outstanding, ISIN US76243J1051 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rhythm Pharmaceuticals Inc

$RYTM

Health Care · Biotechnology

IR Run Scenarios

$90.78

+1.27%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 414 full-time employees. The company went IPO on 2017-10-05. The firm's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.

Employees

414

Website

rhythmtx.com/

IPO

2017-10-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)